NAC + Mindfulness-Based Cognitive Therapy for Depression

(NAC+MIND Trial)

This trial explores how combining mindfulness-based cognitive therapy with the supplement N-acetylcysteine (NAC) might benefit young people with mild depression. Researchers aim to understand changes in brain networks related to emotion and attention. Participants will receive either NAC or a placebo, combined with either actual or sham mindfulness therapy, over eight weeks. Those who have experienced mild depression and have not recently used psychoactive medications may be eligible. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants a chance to contribute to a treatment nearing widespread availability.

You need to be medication-free for at least 5 half-lives since the last use of a psychoactive medication, except for ADHD stimulants, which you can continue if the dose has been stable for over 2 months before the study.

A previous study found N-acetylcysteine (NAC) to be safe and easy for people to handle, with no major side effects. Research has shown that NAC has been used safely in mental health treatments, including for depression. However, some studies report mixed results regarding its effectiveness in treating depression symptoms.

For mindfulness-based cognitive therapy (MBCT), studies indicate it can be delivered safely and effectively in clinical settings. MBCT has reduced symptoms of depression and helped prevent relapses without major safety concerns.

Researchers are excited about these treatments for depression because they combine N-acetylcysteine (NAC) with mindfulness-based cognitive therapy (MBCT), offering a unique dual approach. NAC is an antioxidant that may help reduce oxidative stress linked to depression, which is a different mechanism compared to traditional antidepressants that typically alter brain chemicals like serotonin. Meanwhile, MBCT focuses on mindfulness techniques to change the way patients think and feel about their experiences, potentially providing a more holistic way to manage depression. This combination aims to address both the biological and psychological aspects of depression, setting it apart from standard medications.

Research has shown that N-acetylcysteine (NAC) can help reduce symptoms of depression. Some studies found it improved mood in people with major depression and bipolar disorder. NAC demonstrated a small improvement in depression scores, suggesting its potential as an additional treatment. In this trial, one group of participants will receive NAC alongside mindfulness-based cognitive therapy (MBCT).